Tech Company Financing Transactions

Pionyr Immunotherapeutics Funding Round

Pionyr Immunotherapeutics, based in San Francisco, secured $62 million from New Enterprise Associates, Mission Bay Capital and OrbiMed.

Transaction Overview

Announced On
12/14/2017
Transaction Type
Venture Equity
Amount
$62,000,000
Round
Series B
Investors

New Enterprise Associates (Lead Investor) (Carol Gallagher)

Mission Bay Capital

OrbiMed (Leon Chen)

Osage Partners

Sofinnova Ventures (Michael Powell)

SV Health Investors (Joshua Resnick)

Vida Ventures (Arjun Goyal)

Proceeds Purpose
Two programs directed at myeloid tuning in the tumor microenvironment are headed into the clinic.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Tower Pl. 800
San Francisco, CA 94080
USA
Email Address
Overview
Pionyr develops drugs to perform exceptional fine-tuning of immune responses. This goal addresses a current and justified excitement about immunotherapy and introduces technology to rapidly identify and target novel arms of the immune response, within the tumor microenvironment (TME).
Profile
Pionyr Immunotherapeutics LinkedIn Company Profile
Social Media
Pionyr Immunotherapeutics Company Twitter Account
Company News
Pionyr Immunotherapeutics News
Facebook
Pionyr Immunotherapeutics on Facebook
YouTube
Pionyr Immunotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Steven James
  Steven James LinkedIn Profile  Steven James Twitter Account  Steven James News  Steven James on Facebook
Chief Financial Officer
Monte Montgomery
  Monte Montgomery LinkedIn Profile  Monte Montgomery Twitter Account  Monte Montgomery News  Monte Montgomery on Facebook
Chief Medical Officer
Leonard Reyno
  Leonard Reyno LinkedIn Profile  Leonard Reyno Twitter Account  Leonard Reyno News  Leonard Reyno on Facebook
Chief Scientific Officer
Michel Streuli
  Michel Streuli LinkedIn Profile  Michel Streuli Twitter Account  Michel Streuli News  Michel Streuli on Facebook
Vice President
Kevin Baker
  Kevin Baker LinkedIn Profile  Kevin Baker Twitter Account  Kevin Baker News  Kevin Baker on Facebook
Vice President
Evan Greger
  Evan Greger LinkedIn Profile  Evan Greger Twitter Account  Evan Greger News  Evan Greger on Facebook
VP - Bus. Development
Alicia Levey
  Alicia Levey LinkedIn Profile  Alicia Levey Twitter Account  Alicia Levey News  Alicia Levey on Facebook
VP - Operations
Michael Ellis
  Michael Ellis LinkedIn Profile  Michael Ellis Twitter Account  Michael Ellis News  Michael Ellis on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/14/2017: FollowAnalytics venture capital transaction
Next: 12/15/2017: Glo Station venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary